Risk factors for vascular liver diseases Vascular liver diseases Par MarcGuevreguian|2021-03-22T20:46:38+01:00juillet 7th, 2020| Lire la suite
Pitfalls in CALR exon 9 mutation detection Par MarcGuevreguian|2021-03-22T20:44:07+01:00juillet 2nd, 2020| Lire la suite
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma Par MarcGuevreguian|2021-03-22T20:41:42+01:00juin 29th, 2020| Lire la suite
Anemia and hemodilution – Analysis of a single center cohort based on 2858 Red Cell Mass measurements Par MarcGuevreguian|2021-03-22T19:20:25+01:00juin 25th, 2020| Lire la suite
Illuminating novel biological aspects and potential new therapeutic approaches… Par MarcGuevreguian|2021-03-22T19:55:52+01:00juin 20th, 2020| Lire la suite
Patient Experiences with Avelumab in Treatment‑Naïve Metastatic Merkel Cell Carcinoma Par MarcGuevreguian|2021-03-22T20:38:57+01:00mai 30th, 2020| Lire la suite
Avelumab in patients with previously treated metastatic Merkel cell carcinoma Par MarcGuevreguian|2021-03-22T19:49:58+01:00mai 8th, 2020| Lire la suite
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial Par MarcGuevreguian|2021-03-22T20:32:51+01:00avril 23rd, 2020| Lire la suite
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses Par MarcGuevreguian|2021-03-23T10:34:44+01:00mars 23rd, 2020| Lire la suite
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria Par MarcGuevreguian|2021-03-23T09:42:36+01:00mars 19th, 2020| Lire la suite
